Schizophrenia-relevant behaviors in a genetic mouse model of constitutive Nurr1 deficiency

Genes, Brain and Behavior

Volumn 10, Issue 5, 2011, Pages 589-603

  Vuillermot, S ^a   Joodmardi, E ^b   Perlmann, T ^b   Ove Ogren S ^c   Feldon, J ^a   Meyer, U ^a  

^a ETH ZURICH   (Switzerland)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dopamine; Glutamate; Latent inhibition; Prepulse inhibition; Selective attention

Indexed keywords

DIZOCILPINE; NUCLEAR RECEPTOR RELATED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; COGNITION; FEMALE; GENE DELETION; HETEROZYGOTE; LEARNING; LOCOMOTION; MALE; MOUSE; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; RECOGNITION; SCHIZOPHRENIA; SELECTIVE ATTENTION; SENSORY GATING; SOCIAL INTERACTION; SPATIAL MEMORY; SYMPTOMATOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NUCLEAR RECEPTOR SUBFAMILY 4, GROUP A, MEMBER 2; SCHIZOPHRENIA; SENSORY GATING; SEX FACTORS; STARTLE REACTION;

MUS;

EID: 79960015625     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2011.00698.x     Document Type: Article

References (64)

1. Addy, C., Assaid, C., Hreniuk, D., Stroh, M., Xu, Y., Herring, W.J., Ellenbogen, A., Jinnah, H.A., Kirby, L., Leibowitz, M.T., Stewart, R.M., Tarsy, D., Tetrud, J., Stoch, S.A., Gottesdiener, K. & Wagner, J. (2009) Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol 49, 856-864.
2. Bäckman, C., You, Z.B., Perlmann, T. & Hoffer, B.J. (2003) Elevated locomotor activity without altered striatal dopamine contents in Nurr1 heterozygous mice after acute exposure to methamphetamine. Behav Brain Res 143, 95-100.
3. Braff, D.L., Grillon, C. & Geyer, M.A. (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49, 206-215.
4. Braff, D.L., Geyer, M.A. & Swerdlow, N.R. (2001) Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology 156, 234-258.
5. Brébion, G., David, A.S., Pilowsky, L.S. & Jones, H. (2004) Recognition of visual stimuli and memory for spatial context in schizophrenic patients and healthy volunteers. J Clin Exp Neuropsychol 26, 1093-1102.
6. Brown, V.J. & Bowman, E.M. (2002) Rodent models of prefrontal cortical function. Trends Neurosci 25, 340-343.
7. Buervenich, S., Carmine, A., Arvidsson, M., Xiang, F., Zhang, Z., Sydow, O., Jönsson, E.G., Sedvall, G.C., Leonard, S., Ross, R.G., Freedman, R., Chowdari, K.V., Nimgaonkar, V.L., Perlmann, T., Anvret, M. & Olson, L. (2000) Nurr1 mutations in cases of schizophrenia and manic-depressive disorder. Am J Med Genet 96, 808-813.
8. van den Buuse, M., Garner, B., Gogos, A. & Kusljic, S. (2005) Importance of animal models in schizophrenia research. Aust N Z J Psychiatry 39, 550-557.
9. Carmine, A., Buervenich, S., Galter, D., Jönsson, E.G., Sedvall, G.C., Farde, L., Gustavsson, J.P., Bergman, H., Chowdari, K.V., Nimgaonkar, V.L., Anvret, M., Sydow, O. & Olson, L. (2003) NURR1 promoter polymorphisms: Parkinson's disease, schizophrenia, and personality traits. Am J Med Genet B Neuropsychiatr Genet 120, 51-57.
10. Chu, Y., Le, W., Kompoliti, K., Jankovic, J., Mufson, E.J. & Kordower, J.H. (2006) Nurr1 in Parkinson's disease and related disorders. J Comp Neurol 494, 495-514.
11. Crawley, J.N. (2007) Mouse behavioral assays relevant to the symptoms of autism. Brain Pathol 17, 448-459.
12. Crider, A. (1997) Perseveration in schizophrenia. Schizophr Bull 23, 63-74.
13. Csomor, P.A., Yee, B.K., Feldon, J., Theodoridou, A., Studerus, E. & Vollenweider, F.X. (2009) Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophr Bull 35, 244-255.
14. Cui, X., Pelekanos, M., Burne, T.H., McGrath, J.J. & Eyles, D.W. (2010) Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon. Neurosci Lett 486, 220-223.
15. Dalley, J.W., Cardinal, R.N. & Robbins, T.W. (2004) Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28, 771-784.
16. Dellu, F., Mayo, W., Cherkaoui, J., Le Moal, M. & Simon, H. (1992) A two-trial memory task with automated recording: study in young and aged rats. Brain Res 588, 132-139.
17. Eells, J.B., Lipska, B.K., Yeung, S.K., Misler, J.A. & Nikodem, V.M. (2002) Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity. Behav Brain Res 17, 267-275.
18. Eells, J.B., Misler, J.A. & Nikodem, V.M. (2006) Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in Nurr1-null heterozygous mice. Neuroscience 140, 1117-1126.
19. Eyles, D.W., Feron, F., Cui, X., Kesby, J.P., Harms, L.H., Ko, P., McGrath, J.J. & Burne, T.H. (2009) Developmental vitamin D deficiency causes abnormal brain development. Psychoneuroendocrinology 34, 247-257.
20. Feldon, J. & Weiner, I. (1992) From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res 26, 345-366.
21. Foussias, G. & Remington, G. (2010) Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull 36, 356-359.
22. Geyer, M.A. & Swerdlow, N.R. (1998) Measurement of startle response, prepulse inhibition and habituation. Curr Protoc Neurosci 8, 1-15.
23. Grimes, D.A., Han, F., Panisset, M., Racacho, L., Xiao, F., Zou, R., Westaff, K. & Bulman, D.E. (2006) Translated mutation in the Nurr1 gene as a cause for Parkinson's disease. Mov Disord 21, 906-909.
24. Guillin, O., Abi-Dargham, A. & Laruelle, M. (2007) Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78, 1-39.
25. Hoffman, H.S. & Searle, J.L. (1965) Acoustic variables in the modification of the startle reaction in the rat. J Comp Physiol Psychol 60, 53-58.
26. Howes, O.D. & Kapur, S. (2009) The dopamine hypothesis of schizophrenia: version III - the final common pathway. Schizophr Bull 35, 549-562.
27. Huang, Y., Cheung, L., Rowe, D. & Halliday, G. (2004) Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev 46, 44-70.
28. Jankovic, J., Chen, S. & Le, W.D. (2005) The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 77, 128-138.
29. Jiang, C., Wan, X., He, Y., Pan, T., Jankovic, J. & Le, W. (2005) Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol 191, 154-162.
30. Kadkhodaei, B., Ito, T., Joodmardi, E., Mattsson, B., Rouillard, C., Carta, M., Muramatsu, S., Sumi-Ichinose, C., Nomura, T., Metzger, D., Chambon, P., Lindqvist, E., Larsson, N.G., Olson, L., Björklund, A., Ichinose, H. & Perlmann, T. (2009) Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci 29, 15923-15932.
31. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B. Jr. & Charney, D.S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51, 199-214.
32. Lahti, A.C., Koffel, B.L., LaPorte, D. & Tamminga, D.A. (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13, 9-19.
33. Lahti, A.C., Weiler, M.A., Tamara Michaelidis, B.A., Parwani, A. & Tamminga, C.A. (2001) Effects of ketamine in normal and schizophrenia volunteers. Neuropsychopharmacology 23, 223-239.
34. Le, W., Conneely, O.M., Zou, L., He, Y., Saucedo-Cardenas, O., Jankovic, J., Mosier, D.R. & Appel, S.H. (1999a) Selective agenesis of mesencephalic DA neurons in Nurr1-deficient mice. Exp Neurol 159, 451-458.
35. Leng, A., Yee, B.K., Feldon, J. & Ferger, B. (2004) Acoustic startle response, prepulse inhibition, and spontaneous locomotor activity in MPTP-treated mice. Behav Brain Res 154, 449-456.
36. Meyer, U. & Feldon, J. (2009) Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res 204, 322-334.
37. Meyer, U. & Feldon, J. (2010) Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 90, 285-326.
38. Meyer, U., Chang, D.L., Feldon, J. & Yee, B.K. (2004) Expression of the CS- and US-pre-exposure effects in the conditioned taste aversion paradigm and their abolition following systemic amphetamine treatment in C57BL6/J mice. Neuropsychopharmacology 29, 2140-2148.
39. Meyer, U., Feldon, J., Schedlowski, M. & Yee, B.K. (2005) Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 29, 913-947.
40. Meyer, U., Engler, A., Weber, L., Schedlowski, M. & Feldon, J. (2008a) Preliminary evidence for a modulation of fetal dopaminergic development by maternal immune activation during pregnancy. Neuroscience 154, 701-709.
41. Meyer, U., Murray, P.J., Urwyler, A., Yee, B.K., Schedlowski, M. & Feldon, J. (2008b) Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry 13, 208-221.
42. Meyer, U., Nyffeler, M., Yee, B.K., Knuesel, I. & Feldon, J. (2008c) Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 22, 469-486.
43. Mohn, A.R., Gainetdinov, R.R., Caron, M.G. & Koller, B.H. (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436.
44. Perriol, M.P., Dujardin, K., Derambure, P., Marcq, A., Bourriez, J.L., Laureau, E., Pasquier, F., Defebvre, L. & Destée, A. (2005) Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson's disease dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry 76, 106-108.
45. Perry, W., Minassian, A., Paulus, M.P., Young, J.W., Kincaid, M.J., Ferguson, E.J., Henry, B.L., Zhuang, X., Masten, V.L., Sharp, R.F. & Geyer, M.A. (2009) A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66, 1072-1080.
46. Powell, C.M. & Miyakawa, T. (2006) Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry 59, 1198-1207.
47. Rojas, P., Joodmardi, E., Hong, Y., Perlmann, T. & Ogren, S.O. (2007) Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol Psychiatry 12, 756-766.
48. Rojas, P., Joodmardi, E., Perlmann, T. & Ogren, S.O. (2010) Rapid increase of Nurr1 mRNA expression in limbic and cortical brain structures related to coping with depression-like behavior in mice. J Neurosci Res 88, 2284-2293.
49. Ruano, D., Macedo, A., Dourado, A., Soares, M.J., Valente, J., Coelho, I., Santos, V., Azevedo, M.H., Goodman, A., Hutz, M.H., Gama, C., Lobato, M.I., Belmonte-de-Abreu, P. & Palha, J.A. (2004) NR4A2 and schizophrenia: lack of association in a Portuguese/Brazilian study. Am J Med Genet B Neuropsychiatr Genet 128, 41-45.
50. Saucedo-Cardenas, O., Quintana-Hau, J.D., Le, W.D., Smidt, M.P., Cox, J.J., De Mayo, F., Burbach, J.P. & Conneely, O.M. (1998) Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci U S A 95, 4013-4018.
51. Smidt, M.P. & Burbach, J.P. (2007) How to make a mesodiencephalic dopaminergic neuron. Nat Rev Neurosci 8, 21-32.
52. Swerdlow, N.R. & Geyer, M.A. (1998) Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24, 285-301.
53. Swerdlow, N.R., Geyer, M.A. & Braff, D.L. (2001) Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 156, 194-215.
54. Tamminga, C.A. & Holcomb, H.H. (2005) Phenotype of schizophrenia: a review and formulation. Mol Psychiatry 10, 27-39.
55. Tandon, R., Nasrallah, H.A. & Keshavan, M.S. (2009) Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Research 110, 1-23.
56. Valls-Solé, J. (2004) Function and dysfunction of the startle reaction in humans. Rev Neurol 39, 946-955.
57. Vuillermot, S., Weber, L., Feldon, J. & Meyer, U. (2010) A longitudinal examination of the neurodevelopmental impact of prenatal immune activation in mice reveals primary defects in dopaminergic development relevant to schizophrenia. J Neurosci 30, 1270-1287.
58. Weiner, I. (2003) The two-headed latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169, 257-297.
59. Wallén, A., Zetterström, R.H., Solomin, L., Arvidsson, M., Olson, L. & Perlmann, T. (1999) Fate of mesencephalic AHD2-expressing dopamine progenitor cells in Nurr1 mutant mice. Exp Cell Res 253, 737-746.
60. Xing, G., Zhang, L., Russell, S. & Post, R. (2006) Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders. Schizophr Res 84, 36-56.
61. Yee, B.K. & Feldon, J. (2009) Distinct forms of prepulse inhibition disruption distinguishable by the associated changes in prepulse-elicited reaction. Behav Brain Res 204, 387-395.
62. Yee, B.K., Chang, D.L. & Feldon, J. (2004) The effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice. Neuropsychopharmacology 29, 1865-1877.
63. Zetterström, R., Solomin, L., Jansson, L., Hoffer, B.J., Olson, L. & Perlmann, T. (1997) Dopamine neuron agenesis in Nurr1-deficient mice. Science 276, 248-250.
64. Zetterström, R.H., Williams, R., Perlmann, T. & Olson, L. (1996) Cellular expression of the immediate early transcription factors Nurr1 and NGFI-B suggests a gene regulatory role in several brain regions including the nigrostriatal dopamine system. Brain Res Mol Brain Res 41, 111-120.